6-Brom-5-oxo-hexansaeure-(1)-aethylester | 39826-30-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-Brom-5-oxo-hexansaeure-(1)-aethylester
• 英文别名: Ethyl 6-bromo-5-oxohexanoate
• CAS: 39826-30-7
• 化学式: C₈H₁₃BrO₃
• 分子量: 237.093
• InChiKey: IYIPTLSLNPJBTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-Brom-5-oxo-hexansaeure-(1)-aethylester 在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 6-azido-5-oxohexanoate
  参考文献：
  名称：

  Probing the active site of rat porphobilinogen synthase using newly developed inhibitors

  摘要：

  The structurally related tetrapyrrolic pigments are a group of natural products that participate in many of the fundamental biosynthetic and catabolic processes of living organisms. Porphobilinogen synthase catalyzes a rate-limiting step for the biosyntheses of tetrapyrrolic natural products. In the present study, a variety of new substrate analogs and reaction intermediate analogs were synthesized, which were used as probes for studying the active site of rat porphobilinogen synthase. The compounds 1, 3, 6, 9, 14, 16, and 28 were found to be competitive inhibitors of rat porphobilinogen synthase with inhibition constants ranging from 0.96 to 73.04 mM. Compounds 7, 10, 12, 13, 15, 17, 18, and 26 were found to be irreversible enzyme inhibitors. For irreversible inhibitors, loose-binding inhibitors were found to give stronger inactivation. The amino group and carboxyl group of the analogs were found to be important for their binding to the enzyme. This study increased our understanding of the active site of porphobilinogen synthase. (C) 2008 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bioorg.2008.11.001
• 作为产物：
  描述：

  4-乙酰基丁酸乙酯 在 溴 作用下， 以 甲醇 为溶剂， 生成 6-Brom-5-oxo-hexansaeure-(1)-aethylester
  参考文献：
  名称：

  Probing the active site of rat porphobilinogen synthase using newly developed inhibitors

  摘要：

  The structurally related tetrapyrrolic pigments are a group of natural products that participate in many of the fundamental biosynthetic and catabolic processes of living organisms. Porphobilinogen synthase catalyzes a rate-limiting step for the biosyntheses of tetrapyrrolic natural products. In the present study, a variety of new substrate analogs and reaction intermediate analogs were synthesized, which were used as probes for studying the active site of rat porphobilinogen synthase. The compounds 1, 3, 6, 9, 14, 16, and 28 were found to be competitive inhibitors of rat porphobilinogen synthase with inhibition constants ranging from 0.96 to 73.04 mM. Compounds 7, 10, 12, 13, 15, 17, 18, and 26 were found to be irreversible enzyme inhibitors. For irreversible inhibitors, loose-binding inhibitors were found to give stronger inactivation. The amino group and carboxyl group of the analogs were found to be important for their binding to the enzyme. This study increased our understanding of the active site of porphobilinogen synthase. (C) 2008 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bioorg.2008.11.001

文献信息

• 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione compounds, processes for preparing and a pharmaceutical composition comprising the same
  申请人：Merck & Co., Inc.

  公开号：EP0025232A1

  公开（公告）日：1981-03-18

  Novel 4-(substituted thiazolyl) -3-hydroxy-3-pyrroline -2,5-diones and processes for preparing them are disclosed. The novel compounds have the structure wherein n is 0 to 2; m is 0 to 3; R1, R2 and R3 are independently hydrogen, halogen, loweralkyl having 1 to 6 carbons, trifluoromethyl, and loweralkoxy having 1 to 6 carbons or pharmaceutically acceptable salts thereof, with the proviso that the substituents on the thiazolyl ring are not adjacent. They inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate renal lithiasis.

  本发明公开了新型 4-（取代的噻唑基）-3-羟基-3-吡咯啉-2,5-二酮及其制备工艺。 新型化合物具有如下结构：n 为 0 至 2；m 为 0 至 3；R1、R2 和 R3 独立地为氢、卤素、具有 1 至 6 个碳原子的低级烷基、三氟甲基和具有 1 至 6 个碳原子的低级烷氧基或其药学上可接受的盐，但噻唑环上的取代基不相邻。 它们能抑制乙醇酸氧化酶，因此可用于治疗和预防草酸钙肾性结石。
• US4298743A
  申请人：——

  公开号：US4298743A

  公开（公告）日：1981-11-03